These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18354195)

  • 1. Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection.
    Schnickel GT; Bastani S; Hsieh GR; Shefizadeh A; Bhatia R; Fishbein MC; Belperio J; Ardehali A
    J Immunol; 2008 Apr; 180(7):4714-21. PubMed ID: 18354195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of CXCR3 and CCR5 in allograft rejection.
    Schnickel GT; Hsieh GR; Garcia C; Shefizadeh A; Fishbein MC; Ardehali A
    Transplant Proc; 2006 Dec; 38(10):3221-4. PubMed ID: 17175228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of recipient CCR5 promotes early and increased allospecific antibody responses to cardiac allografts.
    Amano H; Bickerstaff A; Orosz CG; Novick AC; Toma H; Fairchild RL
    J Immunol; 2005 May; 174(10):6499-508. PubMed ID: 15879153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection.
    Akashi S; Sho M; Kashizuka H; Hamada K; Ikeda N; Kuzumoto Y; Tsurui Y; Nomi T; Mizuno T; Kanehiro H; Hisanaga M; Ko S; Nakajima Y
    Transplantation; 2005 Aug; 80(3):378-84. PubMed ID: 16082334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR5 blockade in combination with rapamycin prolongs cardiac allograft survival in mice.
    Li J; Zhang K; Ye P; Wang S; Xia J
    Clin Exp Immunol; 2009 Sep; 157(3):437-45. PubMed ID: 19664153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monokine induced by IFN-gamma is a dominant factor directing T cells into murine cardiac allografts during acute rejection.
    Miura M; Morita K; Kobayashi H; Hamilton TA; Burdick MD; Strieter RM; Fairchild RL
    J Immunol; 2001 Sep; 167(6):3494-504. PubMed ID: 11544343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients.
    Nozaki T; Amano H; Bickerstaff A; Orosz CG; Novick AC; Tanabe K; Fairchild RL
    J Immunol; 2007 Oct; 179(8):5238-45. PubMed ID: 17911609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of CCR5 and CXCR3 attenuates murine acute graft-versus-host disease through modulating donor-derived T-cell distribution and function.
    Tang B; Qin C; Liu H; Miao S; Xue C; Wang Z; Zhang Y; Dong Y; Liu W; Ren H
    Int Immunol; 2024 Sep; 36(10):541-552. PubMed ID: 38778574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection.
    Panzer U; Reinking RR; Steinmetz OM; Zahner G; Sudbeck U; Fehr S; Pfalzer B; Schneider A; Thaiss F; Mack M; Conrad S; Huland H; Helmchen U; Stahl RA
    Transplantation; 2004 Nov; 78(9):1341-50. PubMed ID: 15548973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IP-10-induced recruitment of CXCR3 host T cells is required for small bowel allograft rejection.
    Zhang Z; Kaptanoglu L; Tang Y; Ivancic D; Rao SM; Luster A; Barrett TA; Fryer J
    Gastroenterology; 2004 Mar; 126(3):809-18. PubMed ID: 14988835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of acute and chronic cardiac allograft rejection in mice by inhibition of chemokine receptor 5 in combination with cyclosporine A.
    Li J; Xia J; Zhang K; Xu L
    J Surg Res; 2009 Nov; 157(1):81-90. PubMed ID: 19577762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection.
    Yun JJ; Whiting D; Fischbein MP; Banerji A; Irie Y; Stein D; Fishbein MC; Proudfoot AE; Laks H; Berliner JA; Ardehali A
    Circulation; 2004 Feb; 109(7):932-7. PubMed ID: 14757698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking of CCR5 and CXCR3 suppresses the infiltration of macrophages in acute renal allograft rejection.
    Kakuta Y; Okumi M; Miyagawa S; Tsutahara K; Abe T; Yazawa K; Matsunami K; Otsuka H; Takahara S; Nonomura N
    Transplantation; 2012 Jan; 93(1):24-31. PubMed ID: 22124337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection.
    Abdi R; Smith RN; Makhlouf L; Najafian N; Luster AD; Auchincloss H; Sayegh MH
    Diabetes; 2002 Aug; 51(8):2489-95. PubMed ID: 12145162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial changes in the expression of CXCR3 and CCR5 on peripheral blood lymphocytes following human renal transplantation.
    Inston N; Drayson M; Ready A; Cockwell P
    Exp Clin Transplant; 2007 Dec; 5(2):638-42. PubMed ID: 18194114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement of the chemokine receptor CXCR3 for acute allograft rejection.
    Hancock WW; Lu B; Gao W; Csizmadia V; Faia K; King JA; Smiley ST; Ling M; Gerard NP; Gerard C
    J Exp Med; 2000 Nov; 192(10):1515-20. PubMed ID: 11085753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine receptor blockade with a synthetic nonpeptide compound attenuates cardiac allograft vasculopathy.
    Bastani S; Sherman W; Schnickel GT; Hsieh GR; Bhatia R; Fishbein MC; Ardehali A
    Transplantation; 2009 Oct; 88(8):995-1001. PubMed ID: 19855245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allografts.
    Kohei N; Tanaka T; Tanabe K; Masumori N; Dvorina N; Valujskikh A; Baldwin WM; Fairchild RL
    Kidney Int; 2016 Jun; 89(6):1293-306. PubMed ID: 27165816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody.
    Uppaluri R; Sheehan KC; Wang L; Bui JD; Brotman JJ; Lu B; Gerard C; Hancock WW; Schreiber RD
    Transplantation; 2008 Jul; 86(1):137-47. PubMed ID: 18622291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In the absence of natural killer cell activation donor-specific antibody mediates chronic, but not acute, kidney allograft rejection.
    Yagisawa T; Tanaka T; Miyairi S; Tanabe K; Dvorina N; Yokoyama WM; Valujskikh A; Baldwin WM; Fairchild RL
    Kidney Int; 2019 Feb; 95(2):350-362. PubMed ID: 30503624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.